| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
The objective of this study is to determine a reasonable strategy for treatment of secondary hyperparathyroidism based on clinical and cost-effectiveness.In the cost-effectiveness analysis of cinacalcet hydrochloride for severe secondary hyperparathyroidism, we showed that the use of cinacalcet is likely to be cost-effective for only those who cannot undergo parathyroidectomy (Komaba H et al. Am J Kidney Dis 60: 262-271, 2012).In the cost-effectiveness analysis of 99m_Tc-MIBI scintigraphy, we showed that this method is likely to be cost-effective for preoperative identification of ectopic parathyroid glands in hemodialysis patients with persistent or recurrent secondary hyperparathyroidism (Komaba H et al. 49th ERA-EDTA Congress, Paris).Finally, using retrospective cohort data of 2,292 maintenance hemodialysis patients, we demonstrated that treatment with lanthanum carbonate, a novel phosphate bidder, is independently associated with survival benefit among those with uncontrolled hyperphosphatemia (Komaba H et al.50th ERA-EDTA Congress, Istanbul).
|
